<DOC>
	<DOC>NCT01675362</DOC>
	<brief_summary>This study will be conducted to evaluate the protective effects and mechanisms of antioxidants (vitamins A, C, E and Selenium), calcium channel blocker (Verapamil) and angiotensin receptor blocker (Lozartan) against shock wave induced renal injuries.</brief_summary>
	<brief_title>Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury?</brief_title>
	<detailed_description>The protective effect will be evaluated via estimation of the changes in renal tubular enzyme (NGAL) and detection of albumen levels in urine. The mechanisms of protection will be investigated by estimation of renal perfusion and functional changes using dynamic MRI.</detailed_description>
	<mesh_term>Calculi</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1. Well functioning kidney (serum creatinine &lt;1.2 mg/dl). 2. Solitary renal stone. 3. Size: 25 mm or less in the largest diameter. 1. Contraindications to ESWL 2. Previous surgical treatment of renal stones. 3. Congenital renal anomalies. 4. Pediatric patients (age &lt;18 years). 5. Patients with Diabetes or hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Extracorporeal shockwave lithotripsy (ESWL)</keyword>
	<keyword>Kidney calculi</keyword>
	<keyword>Renal protection</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Calcium channel blockers</keyword>
	<keyword>Angiotensin receptor blockers</keyword>
</DOC>